Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ORKAFirst patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026
August 11, 2025Earnings
Read more →Oruka Therapeutics Initiates Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-002, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-17A And IL-17F
ORKAMay 20, 2025
Read more →Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $40 Price Target
ORKAMay 15, 2025
Read more →Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate
ORKAMay 14, 2025
Read more →Oruka Therapeutics Announces Preclinical Data For ORKA-002 At The 2025 AAD Annual Meeting
ORKAMarch 7, 2025
Read more →Oruka Therapeutics Q4 2024 GAAP EPS $(0.49) Beats $(0.79) Estimate
ORKAMarch 6, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
ORKADecember 20, 2024
Read more →Oruka Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-001, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-23p19
ORKADecember 19, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
ORKAOctober 31, 2024
Read more →